AVEO - AVEO Pharmaceuticals, Inc.
| Previous Close | 3.07 |
| Open | 3.03 |
| Bid | 3.00 x 3500 |
| Ask | 3.01 x 2400 |
| Day's Range | 2.90 - 3.05 |
| 52 Week Range | 0.50 - 4.24 |
| Volume | 816,845 |
| Avg. Volume | 4,756,987 |
| Market Cap | 461.55M |
| Beta | 1.25 |
| PE Ratio (TTM) | -4.83 |
| EPS (TTM) | -0.62 |
| Earnings Date | May 11, 2017 - May 12, 2017 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 6.00 |
- Capital Cube•yesterday
AVEO Pharmaceuticals, Inc. – Value Analysis (NASDAQ:AVEO) : October 18, 2017
Categories: Fundamental Analysis Yahoo FinanceClick here to see latest analysis Capitalcube gives AVEO Pharmaceuticals, Inc. a score of 7. Our analysis is based on comparing AVEO Pharmaceuticals, Inc. with the following peers – Biogen Inc., Regeneron Pharmaceuticals, Inc., ArQule, Inc., GTx, Inc., Bristol-Myers Squibb Company, Merrimack Pharmaceuticals, Inc., Amgen Inc. and Eli Lilly and Company (BIIB-US, REGN-US, ARQL-US, GTXI-US, ... Read more (Read more...)
- Motley Fool•2 days ago
Here's Why AVEO Pharmaceuticals Dropped as Much as 16.3% Today
Shares have seen increased volatility despite the company gaining its first-ever marketing approval recently.
Capital Cube•2 days agoAVEO Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : AVEO-US : October 17, 2017
Categories: ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for AVEO Pharmaceuticals, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bearish Closing Price above/below 200 Day Moving Average Bullish ... Read more (Read more...)
- Business Wire•3 days ago
AVEO Oncology Announces Phase 1 Results from TiNivo Study to be Presented at the 16th International Kidney Cancer Symposium
AVEO Oncology today announced that results from the Phase 1 portion of the Phase 1/2 TiNivo study will be presented in an oral presentation at the 16th International Kidney Cancer Symposium, to be held November 3-4, 2017 in Miami.
- ACCESSWIRE•10 days ago
Today's Research Reports on Trending Tickers: AVEO Pharmaceuticals and Novavax
NEW YORK, NY / ACCESSWIRE / October 9, 2017 / U.S. markets pulled back Friday as data showed U.S. nonfarm jobs declined for the first time in seven years. The Dow Jones Industrial Average declined 0.01 ...
- ACCESSWIRE•10 days ago
Featured Company News - AVEO Declares Completion of TIVO-3 Study Futility Analysis
Research Desk Line-up: Forward Pharma Post Earnings Coverage LONDON, UK / ACCESSWIRE / October 9, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for AVEO ...
- Business Wire•14 days ago
AVEO Oncology Announces Completion of TIVO-3 Study Futility Analysis with No Changes to Study Protocol
AVEO Oncology today announced the completion of a pre-planned futility analysis of the Phase 3 TIVO-3 trial, the Company’s randomized, controlled, multi-center, open-label study to compare FOTIVDA® to sorafenib in subjects with refractory advanced renal cell carcinoma .
- Forbes•14 days ago
Two Techs And Two Biotechs Breaking Out
Here are two biotech and two tech stocks that are breaking out technically.
- MarketWatch•14 days ago
Harry Boxer’s four stocks that are breaking out this week
In focus: Amicus Therapeutics, AVEO Pharmaceuticals, AXT and Dynavax Technologies.
- Capital Cube•23 days ago
ETFs with exposure to AVEO Pharmaceuticals, Inc. : September 26, 2017
Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to AVEO Pharmaceuticals, Inc. Here are 5 ETFs with the largest exposure to AVEO-US. Comparing the performance and risk of AVEO Pharmaceuticals, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)
- Business Wire•29 days ago
AVEO Oncology and EUSA Pharma Announce TiNivo Combination Study Opt-in
AVEO Oncology and EUSA Pharma today announced that EUSA Pharma, under its multi-territory licensing agreement with AVEO for FOTIVDA® , has opted into the Phase 1/2 TiNivo study.
- Simply Wall St.•last month
Should You Have AVEO Pharmaceuticals Inc’s (AVEO) In Your Portfolio?
If you are a shareholder in AVEO Pharmaceuticals Inc’s (NASDAQ:AVEO), or are thinking about investing in the company, knowing how it contributes to the risk and reward profile of yourRead More...
- Business Wire•last month
AVEO Oncology Announces Receipt of Payments from EUSA Pharma and CANbridge
AVEO Oncology today announced the receipt of a $4 million research and development payment from EUSA Pharma related to the approval of FOTIVDA® for the treatment of adult patients with advanced renal cell carcinoma in Europe, and a $0.5 million milestone payment from CANbridge related to manufacturing development activities for AV-203, AVEO’s clinical-stage ErbB3 inhibitory antibody candidate.
- Capital Cube•last month
ETFs with exposure to AVEO Pharmaceuticals, Inc. : September 9, 2017
Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to AVEO Pharmaceuticals, Inc. Here are 5 ETFs with the largest exposure to AVEO-US. Comparing the performance and risk of AVEO Pharmaceuticals, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)
- ACCESSWIRE•last month
Today's Research Reports on Trending Tickers: AVEO Pharmaceuticals, Inc. and Celldex Therapeutics, Inc.
NEW YORK, NY / ACCESSWIRE / September 8, 2017 / The markets took a hit on Thursday as banking stocks slid on falling rates and after Walt Disney Co. lowered its 2018 earnings guidance. The Dow Jones Industrial ...
- Business Wire•last month
AVEO Oncology to Present at Upcoming Conferences
AVEO Oncology today announced that Michael Bailey, president and chief executive officer, will be presenting at the following investor conferences:
- ACCESSWIRE•2 months ago
Featured Company News - AVEO Pharma's FOTIVDA(R) Licensed in EU for the Treatment of Advanced Renal Cell Carcinoma
Research Desk Line-up: Axovant Sciences Post Earnings Coverage LONDON, UK / ACCESSWIRE / August 30, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for ...
- Motley Fool•2 months ago
Here's Why AVEO Pharmaceuticals Lost as Much as 19% Today
On Monday, the biopharma announced drug approval in Europe. What's going on?
- MarketWatch•2 months ago
AVEO Pharma stock rises 6% after cancer drug gets approved in Europe
AVEO Pharmaceuticals Inc. shares rose as much as 6.2% to $4.01 in extremely heavy morning trade Monday after the company's cancer drug was approved in Europe. The drug, Fotivda, was approved for adults ...
- Business Wire•2 months ago
AVEO Oncology Announces FOTIVDA® (tivozanib) Approved in the European Union for the Treatment of Advanced Renal Cell Carcinoma
AVEO Oncology today announced that the European Commission has approved FOTIVDA® for the treatment of adult patients with advanced renal cell carcinoma in the European Union plus Norway and Iceland.
- Capital Cube•2 months ago
ETFs with exposure to AVEO Pharmaceuticals, Inc. : August 25, 2017
Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to AVEO Pharmaceuticals, Inc. Here are 5 ETFs with the largest exposure to AVEO-US. Comparing the performance and risk of AVEO Pharmaceuticals, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)
Capital Cube•2 months agoAVEO Pharmaceuticals, Inc. :AVEO-US: Earnings Analysis: Q2, 2017 By the Numbers : August 16, 2017
Categories: Yahoo FinanceGet free summary analysis AVEO Pharmaceuticals, Inc. reports financial results for the quarter ended June 30, 2017. We analyze the earnings along side the following peers of AVEO Pharmaceuticals, Inc. – Biogen Inc., Regeneron Pharmaceuticals, Inc., ArQule, Inc., Bristol-Myers Squibb Company, Amgen Inc., Eli Lilly and Company and Merrimack Pharmaceuticals, Inc. (BIIB-US, REGN-US, ARQL-US, BMY-US, ... Read more (Read more...)
- ACCESSWIRE•2 months ago
Today's Research Reports on Trending Tickers: AVEO Pharmaceuticals Inc. and Tandem Diabetes Care Inc.
NEW YORK, NY / ACCESSWIRE / August 15, 2017 / U.S. markets rebounded sharply Monday as geopolitical tensions eased after Secretary of State Rex Tillerson and U.S. Secretary of Defense James Mattis commented ...
- Zacks•2 months ago
AVEO Pharmaceuticals (AVEO) Q2 Loss Narrower than Expected
AVEO Pharmaceuticals (AVEO) reported narrower-than-expected adjusted loss in the second quarter. Its kidney cancer candidate, tivozanib is nearing approval in EU with positive CHMP recommendation.
- Associated Press•2 months ago
AVEO reports 2Q loss
The Cambridge, Massachusetts-based company said it had a loss of 30 cents per share. Losses, adjusted for non-recurring costs, came to 8 cents per share. The cancer drug company posted revenue of $351,000 ...
